Capital Fund Management S.A. Acquires 10,579 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Capital Fund Management S.A. increased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 35.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,233 shares of the biotechnology company's stock after purchasing an additional 10,579 shares during the period. Capital Fund Management S.A. owned approximately 0.09% of United Therapeutics worth $14,196,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of UTHR. Newbridge Financial Services Group Inc. bought a new position in shares of United Therapeutics during the 4th quarter worth approximately $25,000. Millstone Evans Group LLC bought a new position in shares of United Therapeutics in the 4th quarter valued at about $67,000. MassMutual Private Wealth & Trust FSB raised its holdings in United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 58 shares in the last quarter. Jones Financial Companies Lllp boosted its position in United Therapeutics by 678.9% during the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock valued at $104,000 after purchasing an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in shares of United Therapeutics in the fourth quarter valued at $131,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Trading Down 0.1 %

United Therapeutics stock traded down $0.37 during mid-day trading on Thursday, reaching $284.82. The company had a trading volume of 82,672 shares, compared to its average volume of 451,911. The business has a fifty day simple moving average of $319.20 and a 200 day simple moving average of $349.67. The company has a market cap of $12.79 billion, a P/E ratio of 12.46, a P/E/G ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a fifty-two week low of $232.84 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $735.90 million during the quarter, compared to analysts' expectations of $734.74 million. During the same quarter in the prior year, the firm earned $4.36 EPS. Research analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Transactions at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $364.91, for a total value of $3,649,100.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $940,373.07. The trade was a 79.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Raymond Dwek sold 3,000 shares of the business's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $285.16, for a total value of $855,480.00. Following the sale, the director now owns 1,750 shares of the company's stock, valued at approximately $499,030. This represents a 63.16 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 80,500 shares of company stock worth $27,849,960. Company insiders own 11.90% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on UTHR. UBS Group raised their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. StockNews.com cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. Finally, HC Wainwright reissued a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.